Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent

Pharmacotherapy

Volumn 20, Issue 9 II, 2000, Pages

  Projan, S J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; GLYCYLCYCLINE DERIVATIVE; MINOCYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL COUNT; BACTERIOSTASIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESEARCH; ESCHERICHIA COLI; EXPERIMENTAL INFECTION; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEISSERIA GONORRHOEAE; NONHUMAN; RAT; RIBOSOME SUBUNIT; STAPHYLOCOCCUS AUREUS;

EID: 0033818355     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.14.219s.35046     Document Type: Conference Paper

References (2)

1. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
2. Tetracyclines: Antibiotic action, uptake, and resistance mechanisms